We’re excited to release our new clear, concise and clinically relevant infographic Which option to slow myopia?to help you with what we have learnt is the main practitioner need in myopia management, and the most popular discussion topic in the Myopia Profile Facebook group – guidance in selecting the right treatment for your patient. A world first, evidence based decision making tool.
Most eye care practitioners don’t routinely measure axial length in clinical practice, mainly due to lack of access to the instrumentation and its expense. This is not the only reason, though, that axial length (AXL) measurement is a bit of a problematic measure for gauging myopia management success in a clinical setting.
Let’s cut to the chase – until further notice, you can consider low dose (0.05%) atropine, soft multifocal CL’s and OrthoK as all quite similar in terms of their myopia control efficacy, being around 50% on average. A network meta-analysis of sixteen different interventions studied for myopia control showed these options to all have similar efficacy when their refractive and axial length outcomes were put on a level playing field.
We have a convincing evidence base for several optical, one pharmacological and visual environment solutions to reduce the progression of childhood myopia, but nothing guarantees 100% efficacy. Because of this, even in when under a successful myopia management strategy, a child’s myopia may still progress.